Publications found:
36,694
Sort by:
VERTEX PHARMA - Faltering Pipeline and Sales
US$ 140.00
Vertex Pharma (VRTX) 4Q12/FY12 earnings and FY13 guidance (total revenue: ... is banking on success of its Cystic Fibrosis (CF) drugs in the pipeline for resurrection. VRTX endeavors could be too late in competing from ... read our report released on 31st January, 2013 on Vertex titled “Faltering Pipeline and Sales”
January 2013
4 pages
Research Report on China’s Anti-Alzheimer’s Disease (AD) Drug Market, 2013-2017
US$ 2,800.00
... the end of 2011, people aged 60 and above reached 185 million in China, accounting for 13.7% of the population, with an increase of 0.47 percentage point compared ... market development also accelerates. Although the overall market size of China's anti-AD drug market is relatively small, the growth rate is always ...
January 2013
40 pages
SUNPHARMA - Acquisitions to drive the next Growth Wave
US$ 140.00
... this will take time. Leveraging Balance sheet for Acquisition Consolidation of recent acquisitions (URL and DUSA) as well as management’s quest for new ... in US. Management has commented that Sun Pharma will continue to seek acquisitions in US (focus on Derma) and other emerging markets with small to medium ...
January 2013
7 pages
China Insulin Industry Report, 2012-2015
US$ 1,800.00
... analog market in 2011. In April 2012, the insulin phase Ⅲ project of the company held the groundbreaking ceremony. Once the project is put ... . The report highlights the followings: Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc. China insulin ...
January 2013
70 pages
Big Data in Pharma Marketing
US$ 595.00
... on big data and how to work with it. Key Report Features A background to big data A summary of big data sources for pharma and biotech Uses for big data in pharma and biotech marketing Lessons from other industries Challenges facing those wanting to use big data ...
January 2013
76 pages
Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma
US$ 2,500.00
... Value added innovation) versus regulatory pressures to contain costs. Global Biopharmaceutical Outlook 2013-Large Cap Pharma, released by MP Advisors provides ... Emerging Markets and their importance in Growth of Large Cap Pharma 6. Global Pharma -Drugs Losing Patent Protection By 2017 7. Impact of patent ...
December 2012
131 pages
2013 Drugs of Abuse Testing Market: US, Europe, Japan
US$ 6,000.00
... from Venture Planning Group contains 311 pages and 61 tables. 'Drugs of Abuse Testing Market: US, Europe, Japan' is a unique study designed to help current ... start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ...
December 2012
311 pages
Research Report on China's Antidepressant Market, 2013-2017
US$ 2,800.00
... , with the increasing recognition rate of doctors for depression and people's changes in treatment concepts, it is expected that the future potential of China's antidepressant market is fairly great. It is predicted that in coming years, the annual growth rate of market size of China's antidepressants in ...
December 2012
50 pages
Research Report on China's Antifungal Drug Market, 2013-2017
US$ 2,800.00
... of fungi increasingly enhances, so it indicates a sharply rising trend for the clinical application of antifungal drugs. It is expected that in coming years, the annual growth rate of market size of China's antifungal drugs will be over 20%. As for manufacturers, there are many opportunities. ...
December 2012
50 pages
Research Report on China's Diabetes Drug Market, 2013-2017
US$ 2,800.00
... aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached ... the market positions of insulin preparations and Acarbose. The market size of China's diabetes drugs is expected to maintain an annual growth rate of over 18% from ...
December 2012
50 pages
2013 U.S. Pharmacies & Drug Stores Industry-Product & Retail
US$ 199.00
The 2013 U.S. Pharmacies & Drug Stores Industry-Product & Retail report features 2013 current and 2014 forecast estimates on the sales of 61 product lines. The report also includes industry definition, 5-year historical trends on product lines sales. Product lines include ...
December 2012
123 pages
Research Report on China's Antithrombotic Drug Market, 2013-2017
US$ 2,400.00
... , the morbidity and mortality rates of cardiac-cerebral thrombotic diseases in China are higher than that in some developed countries. In addition, patients ... aggregation drugs and thrombolytic drugs. The overall market size of China's antithrombotic drugs is small, but it rapidly grows in recent years. The ...
December 2012
40 pages
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
US$ 396.00
... infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders ... . In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information ...
December 2012
56 pages
Indian Vaccine Industry: Trends & Opportunities (2012-2017)
US$ 800.00
... Indian Vaccine Industry: Trends and Opportunities (2012-2017) offers in-depth study of the global as well as the Indian vaccine industry with detailed discussion on the major segments of the vaccine industry ...
December 2012
62 pages
Research Report on China's Hypolipidemic Drug Market, 2012-2013
US$ 2,400.00
... , the overall morbidity rate of dyslipidemia groups aged 18 and above is over 20% in China, and total patients are over 200 million nationwide. Blood ... , thus occupying a most advantageous position clinically. The overall performance of China's hypolipidemic drugs in the drug market is better than that of the ...
November 2012
55 pages
SUN PHARMA – Outperform, Balance Sheet Leveraging At Play
US$ 140.00
... complex generics to drive growth. In other words, balance sheet would remain the biggest growth driver, both for ... generics are dwindling. DUSA acquisition looks very attractive for Sun Pharma due to (1) DUSA is acquired at a trailing EV / Operating ... of Rs.795 and reiterate our Outperform rating on the stock.
November 2012
7 pages
Biocon - Market Perform, Result Helped By Unsustainable Other Income
US$ 140.00
BIOCON - Market Perform, Result helped by unsustainable other income We reiterate our Market Perform rating on Biocon despite the Q2 FY13 result being higher than our estimates. ... values Syngene at ~11x EV/EBITDA – 16% higher than Biocon’s market valuation. We keep our estimate unchanged. We now rollover our ...
November 2012
7 pages
Social and Mobile Pharma - the State of the Digital Landscape
US$ 445.00
... consumers themselves are able to express concerns online. The influence of social media on pharma marketing is such that even the largest and most ... looks at leading-edge activities such as data mining, investigates the future of mobile access, outlines legislative and regulatory efforts worldwide and offers ...
November 2012
94 pages
Dr Reddy’S Lab - Market Perform, Great Result, Still Growth To Remain Modest
US$ 140.00
INDIA PHARMA Sub: DR REDDY’S LAB - Market Perform, Great Result, Still Growth to Remain Modest We reiterate our Market Perform rating on DRRD with an upward ... our estimate largely due to high growth in the US generics market business (17% Q-o-Q, constant currency). Other expenses remained lower sequentially ...
October 2012
8 pages
Gilead - Life Cycle Management For Hiv And Hcv Pipeline = Upside
US$ 140.00
... Subject: GILEAD – Life Cycle Management for HIV and HCV Pipeline = Upside Abstract 3Q12 earnings (Table 1) and revised upward revenue guidance validates Gilead’s (GILD ... , please read our report released on 1st Nov., 2012, titled, “Life Cycle Management for HIV and HCV Pipeline = Upside”. Report type – Deep ...
October 2012
7 pages
Alexion - Innovative Drugs For Orphan Diseases Focus = Stability!
US$ 140.00
Abstract Alexion (ALXN) products lack any near term competition ... products beyond Soliris. The fall in the stock price of Alexion (ALXN) despite robust 3Q12 earnings presents a long term buying ... read our report released on 31st September, 2012, titled, “ Innovative Drugs for Orphan Diseases Focus = Stability!”
October 2012
5 pages
Ipca - Outperform, Momentum Continues
US$ 140.00
INDIA PHARMA Subject: IPCA – Outperform, Momentum Continues We reiterate our Outperform on Ipca post its Q2 ... forward sales growth will be driven by (1) continuing growth in the anti malarial tender business to WHO ... to US likely from FY13 and (3) continuing growth from India and other branded markets. While we ...
October 2012
7 pages
Lupin - Market Perform, Margin Worry On Base Business
US$ 140.00
INDIA PHARMA Subject: LUPIN - Market Perform, Margin worry on base business Lupin’s Q2FY13 result was largely inline with our estimates, however, ... R&D expense. Ex-branded US generic sales declined sequentially despite Combivir gaining market share in Q2 FY13. All these indicate pressure on the US base ...
October 2012
7 pages
Grifols, Ivig Opportunity In Ad - Dark Knight
US$ 140.00
... core business, bonus upside from positive data of IVIG in AD, and an attractive risk-reward profile, Grifols SA (GRF) is our preferred choice among three ... coverage initiation report released on 22nd Oct., 2012 on GRF titled, “GRIFOLS SA - IVIG Opportunity in AD - Dark Knight”.
October 2012
17 pages
Global Pharmaceutical Market Report & Forecast: 2012-2017
US$ 1,400.00
The global pharmaceutical market is expected to grow at a CAGR of 5% during 2011-2017, exceeding sales worth US$ 1.1 Trillion by 2017. This market, however, is expected to undergo a number of transiti...
October 2012
-
Alzherimer's Drugs Market, 2012-2017
US$ 1,699.00
... five years, from 2012-2017, will see the launch of many new drugs. Scope of the Report The Alzheimer’s drug market (2011-2017) ... III clinical trials. Chapter 8 provides profiles of the key companies in this market. Each company profile includes information such as financial performance, geographical ...
October 2012
117 pages
Competitor Analysis: Pneumococcal and Streptococcal Vaccines
US$ 260.00
... , Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...
October 2012
21 pages
The US Specialty Pharmaceutical Market Report: 2012 Edition
US$ 800.00
... which fall within the bounds of specialty pharmaceuticals. There is no particular definition for specialty pharmaceutical but on the basis of some ... overview of the US specialty pharmaceutical market covering various disease segments and the specialty pharmacy market. The specialty pharma realm is intensely ...
September 2012
65 pages
Data report-Production Situation of Vitamin B2
US$ 1,490.00
... This report provides you concise information about the vitamin B2 industry in China, discovering not only the latest dynamics of production situation and producers ... , but also price, import and export, and the application fields of the vitamin B2 products. Besides, ...
September 2012
13 pages
Competitor Analysis: Tuberculosis Vaccines and Therapeutics
US$ 516.00
... targeting Mycobacterium tuberculosis for prophylaxis and treatment of tuberculosis. In addition, the report lists corporate and public R&D pipelines of Tuberculosis Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action ...
September 2012
70 pages
Global Generic Drugs Industry 2012-2017: Trend, Profit, and Forecast Analysis, September 2012
US$ 1,980.00
... , a leading global management consulting and market research firm, has analyzed the global generic drugs industry and presents its findings in Global Generic Drugs Industry 2012-2017: Trend, Profit, and Forecast Analysis. The industry comprises firms primarily engaged in the development, manufacture, and marketing of generic drugs. The generic ...
September 2012
-
Pharma and Payers – Building Better Relationships
US$ 895.00
Changes in the healthcare landscape have put payers (public and private) under mounting pressure to reduce the cost of care, and given them much greater influence over market access to new medicines.I...
September 2012
67 pages
Competitor Analysis: Malaria Vaccines & Therapeutics
US$ 390.00
... description The present Competitive Intelligence Report about Malaria Vaccines & Therapeutics provides a competitor evaluation in the field of investigational small molecules and ... regions. Each year more than 350 million new cases of Malaria occur, it is one of the world’s most common diseases. People with ...
August 2012
64 pages
Competitor Analysis: CMV Vaccines & Therapeutics
US$ 247.00
... approved for treatment or prevention of CMV disease, such as ganciclovir, or hyperimmune globulin preparations, but no specific CMV vaccine is approved. The present Competitor Analysis describes the R&D pipeline of new molecular entities including vaccines, monoclonal antibodies, peptides, cellular therapy ...
August 2012
23 pages
Pharma Reputations: Managing Perceptions
US$ 645.00
Pharma is no stranger to the idea of nurturing and defending corporate reputations. But in this hyper-connected world, Likes and Tweets are replacing traditional authority sources and creating a compl...
August 2012
69 pages
Pharma's Future Role in CME
US$ 595.00
... Dossier report: Pharma’s Future Role in CME. REPORT OVERVIEW Save time and effort by reviewing forecasts from 10 leading figures in the US and European CME fields ... role in future CME productions, or strategically direct these from the background. KEY REPORT FEATURES Recent and expected US and European CME regulations Latest pharma ...
August 2012
62 pages
